U.S. IPO window reopens; Medline eyes mega-IPO

Liquidity returning for quality names (Klarna, Figure, LB Pharma). Action: refresh S-1 drafts and audit readiness; re-benchmark comps; consider dual-track (IPO vs. strategic) exits.